Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations
Release Date: May 25, 2017
Expiration Date: May 31, 2018
Activity Type: Application-based
CE Credits: 1 hour (0.1 CEU), no partial credit for pharmacists
Activity Fee: Free of charge
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Accreditation for Physicians
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
This continuing education activity was planned to meet the needs of clinicians with an interest in venous thromboembolism (VTE), especially primary care providers, emergency room physicians, hospitalists, cardiologists, pulmonologists, vascular surgeons, hematologists, and pharmacists in hospitals and ambulatory care clinics who care for patients with VTE.
Activity Content
Clinical case studies will be used to illustrate approaches for addressing clinical issues related to the use of direct oral anticoagulants (DOACs) for managing venous thromboembolism in three patient populations: patients with cancer-associated thrombosis, kidney disease, and obesity. Strategies for managing potential drug interactions with DOACs will also be discussed.
Learning Objectives
After the conclusion of this application-based educational activity, participants should be able to- Examine the evidence for use of direct oral anticoagulants (DOACs) with venous thromboembolism (VTE) and kidney disease.
- Review the evidence for the use of DOACs in patients with cancer-associated VTE.
- Review data on the use of DOACs for treatment of VTE in patients with obesity.
- Implement an appropriate strategy for managing potential drug interactions with DOACs.
Faculty
Adam C. Cuker, M.D., M.S.
Assistant Professor of Medicine and Pathology & Laboratory Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Adam C. Cuker, M.D., M.S., is Assistant Professor of Medicine and of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine in Philadelphia. He also serves as Director of the Penn Comprehensive Hemophilia and Thrombosis Program and Associate Director of the Penn-CHOP Blood Center for Patient Care and Discovery.
Dr. Cuker received his Doctor of Medicine degree from Yale University in New Haven and completed an internship and residency in internal medicine at Brigham and Women’s Hospital and Harvard Medical School in Boston. He continued his postgraduate training as a fellow in hematology/oncology at the Hospital of the University of Pennsylvania. Dr. Cuker also holds a Master of Science in Translational Research degree from the University of Pennsylvania. He is board certified in internal medicine and hematology and is a fellow of the American College of Physicians.
Dr. Cuker conducts patient-oriented research on heparin-induced thrombocytopenia, venous thromboembolism, and anticoagulation funded by the National Institutes of Health. He is Chair of the forthcoming American Society of Hematology (ASH) guidelines on venous thromboembolism and Chair of the ASH panel on heparin-induced thrombocytopenia.
Paul P. Dobesh, Pharm.D., BCPS-AQ Cardiology, FCCP
Professor of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska
Paul P. Dobesh, Pharm.D., BCPS-AQ Cardiology, FCCP, is Professor of Pharmacy Practice at the University of Nebraska Medical Center (UNMC) College of Pharmacy in Omaha, Nebraska.
Dr. Dobesh earned both his Bachelor of Science in pharmacy and Doctor of Pharmacy degrees from South Dakota State University. He completed a specialty residency in internal medicine at the University of Texas at Austin at Brackenridge Hospital. He is a board-certified pharmacotherapy specialist with added qualifications in cardiology.
Dr. Dobesh currently maintains clinical practice with cardiology services at Nebraska Medical Center. He is responsible for teaching pharmacy and medical students, as well as pharmacy and medical residents. His main lecture topics include ischemic heart disease, antithrombotic therapy, and other cardiology and critical care topics. Dr. Dobesh has conducted research on antiplatelet and antithrombotic therapy, focusing on the real-world use of these therapies and healthcare economics. He has also published book chapters and several manuscripts in this area.
Dr. Dobesh was awarded the Distinguished Educator of the Year Award at the UNMC College of Pharmacy in 2015, an award he received four times since 2007. In 2013, he was honored with the UNMC campuswide Outstanding Educator Award.
Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Guidelines for Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on presentations.
All faculty and planners for ASHP Advantage education activities are qualified and selected by ASHP Advantage and required to disclose any relevant financial relationships with commercial interests. ASHP Advantage identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity.
- Paul P. Dobesh, Pharm.D., BCPS-AQ Cardiology, FCCP, declares that he has served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb and Pfizer Alliance, Daiichi Sankyo, Janssen Pharmaceuticals, Inc., and Portola Pharmaceuticals, Inc. (Faculty)
- Alpesh Amin, M.D., MBA, FACC, MACP, SFHM, declares that he has served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb and Pfizer Alliance, and Portola Pharmaceuticals, Inc. (Steering Committee)
- Toby C. Trujillo, Pharm.D., BCPS-AQ Cardiology, FAHA, FCCP, declares he has served as a consultant for Bristol-Myers Squibb and Pfizer Alliance and Janssen Pharmaceuticals, Inc. (Steering Committee)
- All other faculty and planners report no financial relationships relevant to this activity.
Methods and CE Requirements
This is an online activity consisting of audio and slides, an assessment, and a course evaluation. Participants should claim CE credit for this home-study educational activity only if they have not claimed credit for the live activity. Participants must view the entire presentation, take the activity assessment (a minimum score of 70% is required), and complete the course evaluation to receive CE credit. The handout includes slides and the assessment for your reference.
To access the activity, click "Launch Presentation" below. On the last slide of the presentation you must click the “Close Activity and Process CE” button to link to ASHP’s elearning portal to complete the process for obtaining credit. Per ACPE, CPE credit must be claimed no later than 60 days from the date of the live activity or completion of a home-study activity. CPE credit will be reported directly to CPE Monitor.
Agenda
Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations
Adam C. Cuker, M.D., M.S., and Paul P. Dobesh, Pharm.D., BCPS-AQ Cardiology, FCCP
Launch Presentation (60 minutes)*
*Allow additional time to complete the assessment and evaluation.
